Literature DB >> 10467649

[Coronary vasculopathy after heart transplantation--effect of temporal onset, severity and progression on long-term prognosis].

K Pethig1, K Besser, B Heublein, T Wahlers, W Harringer, A Haverich.   

Abstract

Despite considerable progress in the knowledge about pathophysiology of cardiac allograft vascular disease (CAVD), only few systematic studies are available, characterizing the natural course during long-term follow-up after heart transplantation (HTX). Therefore, we analyzed in 354 heart transplant recipients (305 male, 45.9 +/- 11.2 years, mean observation period 5.8 +/- 3.0 years, range 0.9-12.4 years) the results of 1129 coronary angiograms under the aspects of development, severity, localization, and progression of disease related to the prognosis of patients. As expected an increasing prevalence was found over time with a luminal obstruction > or = 30% in 83% of all patients more than 10 years after HTX. Coronary artery stenosis (> or = 50%) at initial diagnosis was predominantly localized in the LAD (46%) followed by RCX (31%) and RCA (23%). Angiographic risk profiles with an impaired prognosis could be identified in the form of an early development (< 4 years post HTX) of disease (p = 0.03), luminal obstruction > 50% (p = 0.001), and multivessel appearance at first diagnosis (p = 0.02) as well as in progressive forms of CAVD (p = 0.001). Summarizing, CAVD is a frequent finding in HTX recipients. Especially in patients with early onset, progressive, and advanced stages of disease it represents a prognostically limiting complication following HTX. Identification of the natural course is of major importance defining the need and efficacy of future palliative therapeutical approaches.

Entities:  

Mesh:

Year:  1999        PMID: 10467649     DOI: 10.1007/s003920050314

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  1 in total

1.  Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors.

Authors:  K Pethig; V Klauss; B Heublein; H Mudra; A Westphal; C Weber; K Theisen; A Haverich
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.